Ramping Up Development of Nucleic Acid Therapies
BioPharm International
; 36(4):15-17, 2023.
Article
in English
| EMBASE | ID: covidwho-2317268
antisense therapy; article; clustered regularly interspaced short palindromic repeat; gene expression; gene mutation; gene silencing; gene therapy; human; nucleotide sequence; personalized medicine; quality of life; RNA interference; RNAi therapeutics; spinal muscular atrophy; acetylsalicylic acid; antisense oligonucleotide; cholesterol/ec [Endogenous Compound]; guide RNA/ec [Endogenous Compound]; inclisiran; microRNA/ec [Endogenous Compound]; monoclonal antibody; nucleic acid/ec [Endogenous Compound]; nusinersen; SARS-CoV-2 vaccine; small interfering RNA/ec [Endogenous Compound]; transfer RNA/ec [Endogenous Compound]; nucleic acid therapy
Search on Google
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
BioPharm International
Year:
2023
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS